A primer of bone metastases management in breast cancer patients
2008

Managing Bone Metastases in Breast Cancer Patients

Sample size: 859 publication Evidence: high

Author Information

Author(s): Petrut B. MD, Trinkaus M. MD, Simmons C. MD, Clemons M. MB BS MD

Primary Institution: Princess Margaret Hospital

Hypothesis

What are the best practices for managing bone metastases in breast cancer patients using bisphosphonates?

Conclusion

Bisphosphonates significantly reduce the risk and delay the occurrence of skeletal-related events in breast cancer patients with bone metastases.

Supporting Evidence

  • Bisphosphonates significantly reduced the odds of non-vertebral fractures.
  • Patients treated with zoledronic acid had an increased time to first skeletal-related event.
  • Clinical trials showed that bisphosphonates improved pain scores in breast cancer patients.

Takeaway

This study shows that special medicines called bisphosphonates can help breast cancer patients with bone problems feel better and avoid serious issues with their bones.

Methodology

The review discusses bisphosphonate treatment guidelines, evidence from clinical trials, and the use of biochemical markers for predicting treatment outcomes.

Potential Biases

Most trials have enrolled a disproportionate number of patients with bone-only disease, which may not reflect the general population.

Limitations

The study highlights uncertainties regarding the optimal timing and choice of bisphosphonate treatment.

Participant Demographics

The study involved breast cancer patients, particularly those with bone metastases.

Statistical Information

P-Value

p<0.00001

Confidence Interval

95% CI: 0.64 to 0.99

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication